|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms at the androgen receptor-regulating genes and cytokine genes are possible host factors associated with HCC.
|
16673293 |
2006 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our study elucidates a novel mechanism underlying the higher risk of HCC in obese/NAFLD males, through specific DAGs enriched by hepatic lipogenesis to increase the transcriptional activity of hepatic AR, a confirmed risk factor for male HCC.
|
31455870 |
2019 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the association of a trinucleotide (CAG) repeat in the androgen receptor (AR) gene (located on the X chromosome) termed "AR-CAG repeats," levels of plasma testosterone, and the risk of HCC in Taiwanese men.
|
11121465 |
2000 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the mis-sense somatic mutations of AR were rare in HCC but the TNR change was a more common one, which exclusively occurred in males.
|
17230529 |
2007 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Plasma testosterone and estradiol levels and genetic polymorphisms in the hormone-related factors cytochrome P450c17 alpha (CYP17, A1 versus A2 alleles), steroid 5 alpha-reductase type II (SRD5A2, valine [V] versus leucine [L] alleles), and androgen receptor (AR, number of CAG repeats) were assayed among 119 case patients who were diagnosed with HCC during 12 years of follow-up and 238 control subjects.All statistical tests were two-sided.
|
11698569 |
2001 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, few studies have addressed the abnormalities of X chromosome in hepatocellular carcinoma (HCC) except sporadic reports on the deletion of band F1 in X chromosome, and the clonal analysis of methylation pattern of the X chromosome-linked human androgen receptor gene.
|
14969851 |
2004 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
In conclusion, our observations suggest that the AR-CAG alleles may contribute to HCC predisposition among women through a mechanism different from that for men.
|
12085360 |
2002 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
In conclusion, the mis-sense somatic mutations of AR were rare in HCC but the TNR change was a more common one, which exclusively occurred in males.
|
17230529 |
2007 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The association between harboring 2 AR alleles containing longer CAG repeats and HCC was more striking among HBV carriers (age-adjusted OR for more than 22 repeats, 2.23; 95% CI, 1.14-4.34) and particularly prominent among HBV carriers under age 53 years (age-adjusted OR, 3.16; 95% CI, 1.13-8.82).
|
12085360 |
2002 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
For AR CAG longer allele (CAG_L), we found that subjects with longer AR CAG_L repeats had a decreased risk of developing HCC (OR = 0.87 for per CAG_A increase, 95 % CI 0.82-0.96, P = 5.33 × 10(-4)).
|
25217983 |
2014 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?
|
28424556 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, AR's function as a novel ETS-1 co-activator or potentially therapeutic target of HCC has been demonstrated.
|
29312607 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
An AR antagonist was able to block this process, suggesting that AR activation in AR-positive HCC may be therapeutically inhibited as a potential intervention strategy.
|
22819717 |
2012 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this report we describe an androgen receptor assay that utilizes the HepG2 human hepatoma cell line transiently transfected with the human androgen receptor and an androgen-responsive reporter.
|
9705896 |
1998 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together, these preclinical findings suggest that hypoxia may increase the HCC CSC population via altering the AR/miR-520f-3p/SOX9 signaling, and targeting this newly identified signaling with the small molecule, miR-520f-3p, may help in the development of the novel therapy to better suppress the HCC progression.
|
30448543 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we sought to explore the roles and mechanisms of acetylcholine (Ach) and androgen receptor (AR) on regulating the fate determinations of HCC.
|
23620780 |
2013 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, AR directly interacts in vivo with androgen-responsive elements in the regions of promoter and exon 2 of PEG10 gene in HCC cell lines.
|
17369855 |
2007 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results not only help to explain the AR roles in the gender disparity of HCC but also provide a potential new therapy to better suppress HCC via combining sorafenib with NK cell-related immunotherapy.
|
26939703 |
2016 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hepatocellular carcinoma (HCC) is a predominantly male disease in which the androgen receptor (AR) serves an important pathogenic role in hepatocarcinogenesis.
|
28599448 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that targeting the AR, rather than the androgen, could be developed as a new therapy to battle HBV-induced HCC.
|
20484730 |
2010 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combination of sorafenib with AR inhibitors might represent a potential treatment for patients with advanced HCC.
|
28475115 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Androgen receptor (AR) signaling is increasingly recognized as one of the important factors associated with HCC.
|
31337771 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further analysis revealed that the role AR plays in adhesion of HCC cells is governed, at least in part, by its ability to up-regulate β1-integrin and activate the PI3K/AKT pathway.
|
24944078 |
2014 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
More significantly, data collected from our center strongly suggest that ADAR1 expression can effectively predict HCC patients' prognosis and an abnormal overexpression of ADAR1 is positively correlated with AR in HCC.
|
29144509 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Young adult HCC patients (18-39 years' old) were more likely to be female, living in the West and Midwestern United States, and showed decreased androgen receptor, drug resistance and pro-angiogenic protein expression compared to older patients.
|
29254188 |
2017 |